Faeth Therapeutics Inc (FTH): Next-Year EPS Estimate 76.74%
As of 2026-11-12, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 76.74%. Featured in 6 EPS revision reports, most recently on 2026-09-07.
On 2026-11-11, analyst consensus for FTH's next-year EPS growth shifted from 76.84% to 76.74% — a negative change of 0.10 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 8.80%.
What's Driving This
Analysts modestly raised Faeth Therapeutics’ next-year EPS growth estimate from 78.26% to 78.82% on 2026-10-16, a positive revision that serves as the primary structural driver. The FDA Fast Track
Generated 2026-10-27 from news as of 2026-10-27
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 76.74%
- EPS growth this year
- 8.80%
- EPS next quarter (est)
- -$0.85
- Last price
- $10.65
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 76.74% | 8.80% | -$0.85 | $10.65 |
| 2026-11-11 | 76.74% | 8.80% | -$0.85 | $13.35 |
| 2026-11-10 | 76.84% | 9.99% | -$0.83 | $12.92 |
| 2026-11-09 | 76.84% | 9.99% | -$0.83 | $12.68 |
| 2026-11-07 | 76.18% | 12.80% | -$0.85 | $22.05 |
| 2026-11-06 | 76.18% | 12.80% | -$0.85 | $22.05 |
| 2026-11-05 | 76.35% | 12.07% | -$0.83 | $19.92 |
| 2026-11-04 | 76.35% | 12.07% | -$0.83 | $19.99 |
| 2026-11-03 | 77.74% | 9.31% | -$0.80 | $19.65 |
| 2026-11-02 | 78.82% | 9.66% | -$0.78 | $19.23 |
| 2026-10-31 | 78.82% | 9.66% | -$0.78 | $18.69 |
| 2026-10-30 | 78.82% | 9.66% | -$0.78 | $18.69 |
| 2026-10-29 | 78.82% | 9.66% | -$0.78 | $18.75 |
| 2026-10-28 | 78.82% | 9.66% | -$0.78 | $19.20 |
| 2026-10-27 | 78.82% | 9.66% | -$0.78 | $19.11 |
| 2026-10-26 | 78.82% | 9.66% | -$0.78 | $16.83 |
| 2026-10-23 | 78.82% | 9.66% | -$0.78 | $17.08 |
| 2026-10-22 | 78.82% | 9.66% | -$0.78 | $20.10 |
| 2026-10-21 | 78.82% | 9.66% | -$0.78 | $20.57 |
| 2026-10-20 | 78.82% | 9.66% | -$0.78 | $20.79 |
| 2026-10-19 | 78.82% | 9.66% | -$0.78 | $19.44 |
| 2026-10-16 | 78.82% | 9.66% | -$0.78 | $18.80 |
| 2026-10-15 | 78.26% | 9.66% | -$0.78 | $20.60 |
| 2026-10-14 | 78.26% | 9.88% | -$0.78 | $20.00 |
| 2026-10-13 | 78.26% | 9.88% | -$0.78 | $21.51 |
| 2026-10-12 | 78.26% | 9.88% | -$0.78 | $23.25 |
| 2026-10-11 | 78.26% | 9.88% | -$0.78 | $26.03 |
| 2026-10-10 | 78.26% | 9.88% | -$0.78 | $26.03 |
| 2026-10-09 | 78.26% | 9.88% | -$0.78 | $26.03 |
| 2026-10-08 | 78.26% | 9.88% | -$0.78 | $25.61 |
Reports Featuring FTH
- 2026-09-07
MNTK Surges 26.7% as EPS Revisions Signal Renewables Strength
- 2026-09-04
RNXT surges 43% as EPS revisions lift penny stocks
- 2026-06-25
FTH Surges 69.8% on EPS Revision; LILA, CRMT Also Jump
- 2026-06-24
FTH Leads EPS Revision Rally with 68.9% Surge; CRMT, LILA Also Gain
- 2026-06-23
FTH +65%, CRMT +65% Lead EPS Revision Surge; RFIL +29%, LILA +24%
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
Recent News
- Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial CancerBusiness Wire
- Faeth Therapeutics Strengthens Executive Team with Senior Leadership AppointmentsBusiness Wire
- Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific ConferenceBusiness Wire
- Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational UpdatesBusiness Wire
- Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational UpdatesBusiness Wire
- Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst callsThe Fly
- Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in CancerBusiness Wire
- Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Faeth Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 76.74%, based on analyst consensus.
When was the latest EPS estimate revision for FTH?▾
The most recent revision occurred on 2026-11-11, when analysts adjusted the next-year EPS growth estimate from 76.84% to 76.74%.
What sector and industry does Faeth Therapeutics Inc belong to?▾
Faeth Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. FTH appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Faeth Therapeutics Inc (FTH) appears here because it was detected by our daily top-EPS-revision-performer screen.